ArticleFrontiers in immunology2026
Genomic alterations and dynamic molecular residual disease monitoring predict pathological response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Approximately 40-60% of patients with locally advanced esophageal squamous cell carcinoma (ESCC) exhibit suboptimal responses to neoadjuvant chemoimmunotherapy (NCIT), highlighting the need for predictive biomarkers of pathological response. Methods: We prospectively enrolled 29 stage II-III ESCC patients receiving NCIT (albumin-paclitaxel/carboplatin + anti-PD-1). Baseline tumor tissues were firstly analyzed via 437-gene targeted sequencing. Serial preoperative plasma samples collected before NCIT, during NCIT and post-NCIT/pre-surgery, along with baseline tissue, were profiled using a 2365-gene panel for tumor-informed molecular residual disease (MRD) monitoring. Associations between clinicopathological features, genomic alterations, MRD status, and major pathological response (MPR) were evaluated. Results: No clinicopathological feature significantly correlated with MPR. MPR was significantly associated with baseline Conclusions: Dynamic MRD monitoring, particularly post-treatment, provides strong predictive value for pathological response to NCIT in locally advanced ESCC. Integrating baseline
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.